Dr. Reddy’s received FDA approval for two strengths of lenalidomide for the treatment of patients with multiple myeloma.
Formulary Watch
Latest News
All News
Advertisement
AmerisourceBergen/Xcenda survey finds payers believe biosimilars provide costs savings, and they are expected to continuing contracting with manufacturers.
Glass was found in one vial of Cubicin, which treats patients with Staph infections of the skin and blood.
Express Scripts will put the first interchangeable biosimilar insulin on its National Preferred Formulary and exclude Lantus, the reference product.
COVID-19 travel restrictions have hindered the FDA’s ability to inspect European manufacturing facilities for bimekizumab, which is under review for the treatment of patients with psoriasis.
ZIMHI is the second product approved by the FDA to counteract opioid, and it is a high-dose naloxone expected to be launched in the first quarter of 2022.
Most of the solutions have established systems to track patient outcomes over time, and several include performance guarantees as part of their solution.
This low-dose formulation of Biktarvy is for younger children living with HIV.
Narsoplimab was under review at the FDA to treat a complication of stem cell transplants.
The agency cited an open inspection issue at a facility that performs analytical testing of drug substance.
Advertisement
Tyrvaya is a twice daily nasal spray, a first for the treatment of dry eye disease.
The FDA approved Lybalvi in June 2021 to treat schizophrenia and bipolar disorder.
Boehringer Ingelheim will make Cyltezo available when its commercial license begins on July 1, 2023.
The committee’s two-day meeting resulted in recommended approvals for both J&J’s and Moderna’s COVID-19 booster.
Submission is based on extrapolation analysis and results examining the effects of Rexulti in treating symptoms of schizophrenia in patients 13 to 17 years old. The FDA is expected to complete its review in December 2021.
This is the second specialty pharmacy selected to distribute Tavneos, a first-in-class, oral therapy to treat a group of autoimmune diseases characterized by inflammation and damage to small blood vessels.
The FDA has assigned a target action date of April 13, 2022, and plans to hold an advisory committee meeting.
The committee voted unanimously to support the booster given at least six months after the second dose in the original vaccine.
The product contained N-nitrosoirbesartan impurity, a probable human carcinogen.
This is the first anti-PD-1 combination approved for patients with persistent, recurrent or metastatic cervical cancer.
Hikma, which makes the broad-spectrum antibiotic, has experienced manufacturing delays.
The FDA has approved Tavneos, a first-in-class, oral therapy to treat a group of autoimmune diseases characterized by inflammation and damage to small blood vessels.
Verzenio is the first and only CDK4/6 inhibitor approved for this patient population.
Rethmyic is a one-time regenerative tissue-based therapy for children born without a thymus gland.
Drugs with accelerated approval represent a larger amount of Medicaid drug spending relative to their use.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Tubeless AID Systems Boost HRQoL in Type 1 Diabetes
2
Current Guideline Definitions of Barrett’s Esophagus May Fall Short in Detecting Esophageal Cancers
3
Modeling Finds the Timing of Modafinil to Treat Narcolepsy Matters for Efficacy
4
Navigating Female Sexuality in Midlife Requires Provider Nuance and Patient Advocacy
5
